Protara Therapeutics Stock Investor Sentiment

TARA Stock  USD 3.04  0.10  3.40%   
About 57% of all Protara Therapeutics' investors are looking to take a long position. The analysis of the overall investor sentiment regarding Protara Therapeutics suggests that some traders are interested. The current market sentiment, together with Protara Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Protara Therapeutics stock news signals to limit their universe of possible portfolio assets.
  

Protara Therapeutics Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Protara Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
over six months ago at finance.yahoo.com         
Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises 45M Via Equity
Yahoo News
over six months ago at finance.yahoo.com         
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
Yahoo News
over six months ago at finance.yahoo.com         
Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chlo...
Yahoo News
over six months ago at globenewswire.com         
Protara Therapeutics Announces Oversubscribed 45 Million Private Placement Financing
Macroaxis News: globenewswire.com
over six months ago at finance.yahoo.com         
Protara Therapeutics Announces Oversubscribed 45 Million Private Placement Financing
Yahoo News
over six months ago at investing.com         
Protara aligns with FDA on IV Choline Chloride trial for PN patients
Investing News at Macroaxis
over six months ago at investing.com         
Protara secures 45 million in private placement
Investing News at Macroaxis
over six months ago at investing.com         
TARA-002 shows promise in bladder cancer trial
Investing News at Macroaxis
over six months ago at seekingalpha.com         
Protara Therapeutics jumps 23 percent on 45M oversubscribed private financing
seekingalpha News
over six months ago at benzinga.com         
Protara Therapeutics Shares Interim Data From Bladder Cancer Study, Raises 45M Via Equity
benzinga news
over six months ago at investing.com         
Protara shares reiterated at Buy at TD Cowen on trial update
Investing News at Macroaxis
over six months ago at news.google.com         
ArTara Therapeutics Announces Corporate Name Change to Protara Therapeutics - The Globe and Mail
Google News at Macroaxis
over six months ago at news.google.com         
Protara Therapeutics, Inc. Short Interest Update - Defense World
Google News at Macroaxis
over six months ago at investorplace.com         
3 Stocks That Could Help You Retire on a Private Island
sbwire news
over six months ago at news.google.com         
Protara Therapeutics CMO Resigns, Interim Successor Named - TipRanks.com - TipRanks
Google News at Macroaxis
Far too much social signal, news, headlines, and media speculation about Protara Therapeutics that are available to investors today. That information is available publicly through Protara media outlets and privately through word of mouth or via Protara internal channels. However, regardless of the origin, that massive amount of Protara data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Protara Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Protara Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Protara Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Protara Therapeutics alpha.

Protara Therapeutics Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Insider Trading
09/05/2024
2
Disposition of 1900 shares by Opaleye Management Inc. of Protara Therapeutics at 1.8947 subject to Rule 16b-3
09/09/2024
3
Disposition of 1500 shares by Opaleye Management Inc. of Protara Therapeutics at 1.769 subject to Rule 16b-3
09/10/2024
4
Disposition of 1600 shares by Opaleye Management Inc. of Protara Therapeutics at 1.7141 subject to Rule 16b-3
09/11/2024
5
Disposition of 6500 shares by Opaleye Management Inc. of Protara Therapeutics at 1.7089 subject to Rule 16b-3
09/12/2024
6
Dockworkers Reach Deal To End Massive East Coast Strike
10/04/2024
7
Disposition of 3500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.4419 subject to Rule 16b-3
10/30/2024
8
Protara Therapeutics Stock Price Up 0.8 percent Still a Buy
11/08/2024
9
Protara Therapeutics Q3 Earnings Snapshot
11/12/2024
10
Protara Therapeutics to Present New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC at the 25th Annual Meeting of the Society of U...
11/15/2024
11
Disposition of 500 shares by Opaleye Management Inc. of Protara Therapeutics at 3.0021 subject to Rule 16b-3
11/22/2024

Complementary Tools for Protara Stock analysis

When running Protara Therapeutics' price analysis, check to measure Protara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protara Therapeutics is operating at the current time. Most of Protara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Protara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protara Therapeutics' price. Additionally, you may evaluate how the addition of Protara Therapeutics to your portfolios can decrease your overall portfolio volatility.
Global Correlations
Find global opportunities by holding instruments from different markets
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Transaction History
View history of all your transactions and understand their impact on performance
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
CEOs Directory
Screen CEOs from public companies around the world
Sectors
List of equity sectors categorizing publicly traded companies based on their primary business activities
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios